Stock Events

Stock Events

Champions Oncology 

€5.3
0
+€0.34+6.85% Today

Statistics

Day High
5.3
Day Low
5.25
52W High
7.3
52W Low
4.74
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16JulExpected
Q4 2025
Next
-0.04
-0
0.04
0.08
Expected EPS
-0.042599500000000005
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2I3.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap146.36B
Pfizer is involved in oncology drug development and personalized medicine, competing in the cancer treatment market.
Merck
MRK
Mkt Cap275.09B
Merck is a leading pharmaceutical company with a strong focus on cancer therapies, directly competing in the oncology sector.
Novartis
NVS
Mkt Cap278.64B
Novartis is a global healthcare company that has a significant presence in the development of cancer treatments.
Roche
RHHBY
Mkt Cap329.06B
Roche Holding AG specializes in biotech treatments for cancer, making it a direct competitor in oncology research.
Bristol-Myers Squibb
BMY
Mkt Cap114.68B
Bristol Myers Squibb is a pharmaceutical company with a strong emphasis on cancer drugs, competing in the oncology market.
Lilly(Eli) &
LLY
Mkt Cap845.77B
Eli Lilly and Company is engaged in the development of oncology products, competing in the cancer treatment space.
Astrazeneca
AZN
Mkt Cap283.47B
AstraZeneca is a biopharmaceutical company focusing on the development of cancer treatments, making it a competitor.
AMGEN
AMGN
Mkt Cap179.12B
Amgen is a biotech firm with a focus on cancer therapeutics, competing in the oncology market.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences is involved in the research and development of oncology drugs, making it a competitor in the cancer treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap74.95B
Regeneron Pharmaceuticals is engaged in the development of cancer treatments, competing in the oncology sector.

About

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Show more...
CEO
Dr. Ronnie Morris M.D.
Employees
213
Country
Germany
ISIN
US15870P3073

Listings

MU
DE
2I3.MU
STU
DE
2I3.STU
F
DE
2I3.F
XNAS
US
CSBR

0 Comments

Share your thoughts

FAQ

What is Champions Oncology stock price today?▼
The current price of 2I3.STU is €5.3 EUR — it has increased by +6.85% in the past 24 hours. Watch Champions Oncology stock price performance more closely on the chart.
What is Champions Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Champions Oncology stocks are traded under the ticker 2I3.STU.
Is Champions Oncology stock price growing?▼
2I3.STU stock has risen by +0.96% compared to the previous week, the month change is a +8.47% rise, over the last year Champions Oncology has showed a +0.96% increase.
When is the next Champions Oncology earnings date?▼
Champions Oncology is going to release the next earnings report on July 16, 2026.
What were Champions Oncology earnings last quarter?▼
2I3.STU earnings for the last quarter are -0.02 EUR per share, whereas the estimation was 0.08 EUR resulting in a -122.22% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Champions Oncology have?▼
As of May 13, 2026, the company has 213 employees.
In which sector is Champions Oncology located?▼
Champions Oncology operates in the Health & Wellness sector.
When did Champions Oncology complete a stock split?▼
Champions Oncology has not had any recent stock splits.
Where is Champions Oncology headquartered?▼
Champions Oncology is headquartered in Hackensack, Germany.